GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week ...

Don't expect your Part D plans to cover these drugs for weight loss anytime soon.

GLP-1 drugs, such as Ozempic and Wegovy, may slow down the spread of obesity-related cancers, according to researchers ...

Some patients taking GLP-1 drugs to lose weight or manage Type 2 diabetes are discovering an emerging potential side effect ...

The heart failure (HF) treatment landscape continues to evolve rapidly in 2026, with emerging evidence pointing toward a ...

Researchers studied oral GLP-1 medications and a gut bacteria supplement aimed at helping patients maintain weight loss after ...

GLP-1 medications have exploded in popularity over the past few years, and it’s easy to see why. They work. People lose ...

An interview discussing recent research on the association between GLP-1 receptor agonist use and the risk of atrial fibrillation.

NSCLC showed the largest reduction in metastatic progression with GLP-1RAs versus gliptins (HR 0.50), with significant ...

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking ...

Healthcare Investors (HQH) offers high-yield healthcare exposure, but a tight NAV discount and payout risks warrant ...

CMS launches its Medicare GLP-1 Bridge July 1, giving eligible Medicare Part D beneficiaries access to weight-loss GLP-1s at a $50 monthly copay through December 2027. For health systems and pharmacy ...